Hypertrophic cardipmyopathy is a familial heart muscle disorder which may become clinically manifest at any age.14 In adults the natural history is characterised by the slow progression of symptoms and by the occurrence of sudden death. 5 
Results
The 37 patients were followed for a mean of 9 years, during which 18 patients (49%) died: 11 (30%) suddenly, two (five per cent) from cardiac failure, three (eight per cent) perioperatively after myotomy or myectomy, one from endocarditis (three per cent), and one from suicide ( Figure) . Eleven were boys and seven girls. Their age at death was 6 to 23 years (mean 14 years) and their survival was 2 to 13 years (mean 6 years) from the onset of symptoms and 1 to 12 years (mean 6 years) from diagnosis. The age at diagnosis of those who died and survived was identical (1 to 14 years, mean 9 years), however, follow up in the survivors was significantly longer The probability of death=the total number of deaths for the year divided by the adjusted number at risk minus the number of deaths due to other causes. The annual mortality in medically treated patients was 4-8%.
from the onset of symptoms (1 to 21 years, mean 13 years; P<001) and from diagnosis (1 to 21 years, mean 12 years; P<0.01). Nineteen patients were asymptomatic at diagnosis; none of these developed symptoms during a follow up of 2 to 21 years (mean (SD) 10 (7) years), however, four died suddenly. Seven of the 18 patients who presented with symptoms at diagnosis experienced either presyncopal or syncopal episodes or both; 12 had dyspnoea grade 2 and two had dyspnoea grade 3 of the New York Heart Association classification; and eight had exertional chest pain. Seven of the 18 patients died suddenly during a follow up of 1 to 9 years (mean (SD) 5 (3) years). The proportion of patients with chest pain and dyspnoea was similar (Table 1) in those who died suddenly and in the survivors but either presyncope or syncope, or both, were more common in patients who died suddenly (P<0-01).
A clinical summary of those patients who died suddenly is presented in Table 2 . One of the 11 had a normal electrocardiogram at diagnosis; in two (Table 1) . A similar proportion of survivors and those who died suddenly received propranolol (68 and 73% respectively).
Only three patients had progressive symptomatic limitation of exercise tolerance, however, these and the two patients with severe symptoms at diagnosis all died-two in cardiac failure and three perioperatively after myotomy or myectomy. The clinical features of these five patients are presented in Table 3 . They had raised left and right ventricular end diastolic pressures but there was no other electrocardiographic or haemodynamic feature which distinguished them from the survivors.
Discussion
Clinical presentation with hypertrophic cardiomyopathy in childhood was associated with poor prognosis. Approximately half of the patients were dead nine years after diagnosis. This high mortality occurred despite selection criteria which excluded from the study those patients with affected family members who had died suddenly, a group recognised to be at particular risk.7 This study confirmed that children with hypertrophic cardiomyopathy who have severe or progressive symptoms have a grim prognosis.3 More importantly it also showed that those patients with minimal or no functional limitation, who may have been considered to have a benign prognosis also had a poor prognosis with an annual mortality from sudden death of 4-3%. Eleven of the 18 deaths were sudden, and of these only two had severe limitation of exercise tolerance.
Which clinical features identify the child with hypertrophic cardiomyopathy who is at particular risk of sudden death? A history of episodes of impaired consciousness and electrocardiographic evidence of right ventricular hypertrophy were the only clinical, electrocardiographic, or haemodynamic features which distinguished those patients who died suddenly from the survivors. In this study, though episodes of presyncope or syncope were specific (86%), they were not sensitive as approximately half of the children who died suddenly had never experienced symptoms of impaired consciousness. Most patients in this study were evaluated before the availability of good quality echocardiographic recordings, and therefore electrocardiographic criteria were used to assess the presence and magnitude of left and right ventricular hypertrophy. Though electrocardiographic voltage criteria for right ventricular hypertrophy was associated with sudden death, the numbers involved were small and the assessment of right ventricular hypertrophy in the presence of left ventricular hypertrophy is difficult. Prospective echocardiographic confirmation of this finding is warranted. No difference was detected in the incidence or severity of electrocardiographic left ventricular hypertrophy in the survivors and in those who died suddenly. This is consistent with findings in previous studies in which there is a wide spectrum of myocardial hypertrophy both in adults and in children with hypertrophic cardiomyopathy who die suddenly.3 6 13 Hypertrophy is a non-specific marker for the underlying distribution of the disease. Though unproved it is logical to hypothesise that myocardial cellular disarray and myofibrillary disorganisation may predispose to arrhythmia and a myocardium which is electrically unstable. The findings by Maron et 
